Federal Register Notice: FDA is seeking public comment on a proposed collection of information by the Agency: “Application for FDA Approval To Market a New Drug.” This includes all information collection requirements imposed on applicants by the regulations under 21 CFR part 314 who apply for approval of a NDA or ANDA in order to market or to continue to market a drug. To view this notice, click here.
